Clinical and immunological outcome at end of follow-up and after one year of second-line ART.

Patients who switched following first-line treatment failure.
ITT: intention-to-treat analysis, OT: on-treatment analysis, N: number of patients, IQR: interquartile range.
Immunological failure was defined according to the WHO guidelines: a CD4 count after six months of therapy below 100 cells/mm3 or below the pre-therapy count, or a 50% decline from the on-treatment peak CD4 count value. [1]